Gemtuzumab Ozogamicin and High-Dose Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2005-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies, such as gemtuzumab ozogamicin, can locate cancer cells and
either kill them or deliver cancer-killing substances to them without harming normal cells.
Drugs used in chemotherapy, such as cytarabine, use different ways to stop cancer cells from
dividing so they stop growing or die. Combining gemtuzumab ozogamicin with cytarabine may
kill more cancer cells.
PURPOSE: Phase II trial to study the effectiveness of combining gemtuzumab ozogamicin with
high-dose cytarabine in treating patients who have relapsed or refractory acute myeloid
leukemia.